.2 semaglutide | Description, Uses, & Side Effects Ozempic 2 mg/1.5 mL (1.34

SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events owenhaskins Oct 24, 2024 2 min read Headline results from the SOUL cardiovascular outcomes trial show the trial achieved its primary objective by demonstrating a statistically significant and superior reduction in major adverse cardiovascular events (MACE) of 14% for people treated with oral semaglutide compared to placebo (based on treatment policy estimand: treatment effect regardless of treatment adherence)

Its part of a group of meds called GLP-1 receptor agonists

Fun fact: Matrixyl was originally developed by French company Sederma and Procter & Gamble

High success rate when used with diet and exercise

1998 Jul;83(7):2569-72 is fascinating for several reasons